Pen And Injector Drug Delivery Devices Market, By Product, By Therapeutic Use, By End Use, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

The Pen And Injector Drug Delivery Devices Market size was valued at US$113,897.56 Million in 2024, expanding at a CAGR of 9.81% from 2025 to 2032.

Medical professionals use pen and injector drug delivery devices as special equipment which enables them to deliver exact medication amounts into patients through subcutaneous or intramuscular injections while ensuring user safety and medication control. The devices operate through their basic components, which include both manual and electronic injection pens and autoinjectors that come prefilled with specific medications to help patients learn how to inject themselves at home. People use the devices for both chronic and acute medical conditions which include diabetes, obesity and autoimmune disorders and hormonal deficiencies and anaphylaxis because these conditions require patients to receive precise medication doses through scheduled injections. The use of pen and injector drug delivery devices together with traditional vial-and-syringe methods achieves better dosing accuracy because it decreases handling mistakes while providing patients with less painful and anxious injections, thus enhancing patient treatment compliance through home care, which leads to their selection as the primary drug delivery system for modern injectable treatments, including biologics and specialty pharmaceuticals.

Pen And Injector Drug Delivery Devices Market- Market Dynamics

Rising prevalence of chronic diseases

The increasing occurrence of chronic diseases serves as the primary reason for market expansion of pen and injector drug delivery devices because more patients require continuous and precise delivery of injectable medical treatments. Patients with diabetes and obesity and autoimmune disorders and cardiovascular diseases and hormonal imbalances require injectable drugs to manage their conditions, which creates a constant need for delivery systems that users can operate easily. Pen and injector devices enable users to administer their medication independently while they receive precise dosage information which leads to better treatment results than patients would achieve through traditional syringe usage, especially when this method becomes essential for patients who need continuous therapy throughout their lives. Pen and injector devices function as the preferred solution for home healthcare in medical systems and pharmaceutical companies because they enable patients to receive treatment at home while decreasing the need for hospital visits and their usage leads to better health results for patients which drives market expansion.

Pen And Injector Drug Delivery Devices Market- Segmentation Analysis:

By Product

In 2024, the injectors segment holds the largest market share. The growth of this industry occurs because patients with chronic diseases such as rheumatoid arthritis, multiple sclerosis, and diabetes demand user-friendly self-injection equipment which allows them to conduct home treatment. Autoinjectors deliver a simple yet secure and dependable delivery method because they include hidden needles with automatic dosage systems and user-friendly designs which help users to avoid mistakes and experience less needle pain. The worldwide use of autoinjectors increases because patients now prefer to administer their medications themselves, while advances in biologics create new opportunities. SCHOTT Pharma introduced a 5.5 ml large-volume prefillable staked-needle glass syringe through its syriQ BioPure platform in October 2025. This new syringe works with Ypsomed's YpsoMate 5.5 large-volume autoinjector, which allows users to safely and easily inject biologic treatments at their homes. User-centric design and safety innovations build confidence and compliance, which makes this area a major target for producers and medical organizations to concentrate their efforts.

Pen And Injector Drug Delivery Devices Market- Geographical Insights

North America region experiences strong revenue growth. The existing healthcare system together with advanced infrastructure and research and development activities with innovative outcomes creates the engine that drives industry expansion. The market experiences growth because many people suffer from chronic diseases which include diabetes and cancer. Breast cancer is one of the most diagnosed cancers among women in the U.S. According to the American Cancer Society, Inc., in 2024, breast cancer was diagnosed in over 310,000 women in the country. The situation requires development of trustworthy delivery methods that patients can easily use. Advanced device usage increases due to government regulations that create favorable conditions together with strict quality requirements from organizations like the FDA which govern prefilled pens and autoinjectors. The FDA approved the first rapid-acting insulin biosimilar Merilog in February 2025 which comes in two formats a 3 ml prefilled pen and a 10 ml multi-dose vial. The study demonstrates that regulatory assistance enables more people to access pen-based injectable therapies. Ongoing collaboration between pharmaceutical companies and regulatory authorities further supports innovation, market growth, and enhanced patient outcomes across North America.

Pen And Injector Drug Delivery Devices Market- Competitive Landscape:

The pen and injector drug-delivery market exists as a competitive sphere which combines two opposing forces. The market consists of pharmaceutical companies that control their entire production process and create their own pen systems together with their exclusive drug portfolio. The market includes specialized device manufacturers and contract manufacturers who create precise engineering solutions and supply special components and custom products. The market predominantly belongs to major pharmaceutical companies which include Novo Nordisk, Eli Lilly, and Sanofi, because they combine their high-demand biologics products with proprietary pen systems. The pharmaceutical industry depends on Becton Dickinson, Ypsomed, SHL Medical, West Pharmaceutical Services, and Gerresheimer for their reusable and disposable platforms, fill-finish interfaces, and outsourced manufacturing capabilities. The market competition develops through strategic partnerships and licensing agreements and mergers and acquisitions because drugmakers require unique user-friendly pen systems that include connected and electronic pens. Device companies expand their product offerings to develop solutions that will help them secure long-term customer contracts. The market faces pricing challenges because of demand uncertainty in developing regions. The market faces heightened competition because of increasing demand for smart pens which provide data collection and adherence services as well as the expansion of GLP-1 pen products throughout different regions. The competition created opportunities for mid-sized contract manufacturers to acquire business from their larger competitors who dominate the market.

Recent Developments:

In October 2025, Stevanato Group S.p.A. announced a major expansion of its drug delivery system manufacturing capacity in Germany. This move strengthens its presence in Europe. The company added over 2,500 square meters of new production space to its Bad Oeynhausen facility. This includes an ISO 8 cleanroom for injection molding and automated assembly. The multi-million-euro investment improves scalability, supply chain resilience, and support for both proprietary and contract manufacturing of drug delivery devices, including autoinjector and pen injector platforms.
In September 2025, Apiject Systems Corp. announced that it had submitted a New Drug Application to the U.S. FDA for the first injectable medicine delivered with its single-dose, single-use prefilled plastic syringe. This submission included glycopyrrolate, which is given through Apiject’s special injection device. This device combined Blow-Fill-Seal liquid packaging with precisely molded needle hubs. This platform allowed for scalable and cost-effective manufacturing using materials sourced in the U.S., providing an alternative to standard glass vials and prefilled syringes.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PEN AND INJECTOR DRUG DELIVERY DEVICES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen, Inc.
Merck KGaA
Eli Lilly and Company
AstraZeneca plc
Pfizer, Inc.
Sanofi
Teva Pharmaceuticals
Novo Nordisk A/S
Ferring Pharmaceuticals
AbbVie Inc.

GLOBAL PEN AND INJECTOR DRUG DELIVERY DEVICES MARKET, BY PRODUCT - MARKET ANALYSIS, 2019 - 2032

Injectors
GLP-1 Agonists
Hormone Therapies
Biologics
Others
Pen
GLP-1 Agonists
Insulin
Hormone Therapies
Others

GLOBAL PEN AND INJECTOR DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC USE - MARKET ANALYSIS, 2019 - 2032

Autoimmune Disorders
Diabetes Mellitus
Oncology
Obesity
Hormonal Disorders
Others

GLOBAL PEN AND INJECTOR DRUG DELIVERY DEVICES MARKET, BY END USE - MARKET ANALYSIS, 2019 - 2032

Homecare Settings
Hospitals
Others

GLOBAL Pen And Injector Drug Delivery Devices MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more